Skip to main content

Table 2 Significantly altered targets in analyzed cohorts

From: Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects

 

Pericellular fibrosis presence (N = 20)

Pericellular fibrosis absence (N = 25)

P value

AST (U/L)

34.75 ± 25.06

22.62 ± 9.19

0.023

Males

50.0%

19.0%

0.036

Females

35.7%

25%

NS

Advanced fibrosis presence (Score ≥ 3)

60%

9.5%

0.0006

NALP4 mRNA

0.18 ± 0.20

1.12 ± 2.53

0.019

IL1B mRNA

6.17 ± 12.05

14.96 ± 18.21

0.003

 

Portal fibrosis presence (N = 34)

Portal fibrosis absence (N = 11)

P value

Advanced fibrosis presence (Score ≥ 3)

45.2%

0

0.008

NASH

58.1%

20%

0.03

NALP6 mRNA

0.86 ± 0.93

0.38 ± 0.38

0.028

IL-18 (pg/mL)

390.95 pg/mL ± 176.84

246.08 pg/mL ± 103.10

0.022

 

NASH (N = 20)

Non-NASH NAFLD (N = 25)

P value

Gender (Females)

50%

81%

< 0.036

Portal Fibrosis (presence)

1.35 ± 0.67

0.71 ± 0.64

< 0.005

Pericellular Fibrosis (presence)

1.45 ± 0.60

0.05 ± 0.22

< 0.001

Advanced fibrosis (Score ≥ 3)

60%

9.5%

< 0.0006

Degree of lobular inflammation

2.55 ± 1.61

1.52 ± 0.98

< 0.02

AST (U/L)

35.70 ± 24.79

21.71 ± 8.52

< 0.004

NALP 4 mRNA

0.16 ± 0.19

1.14 ± 2.53

< 0.002

NALP 5 mRNA

0.14 ± 0.12

1.24 ± 2.58

< 0.02

NALP 7 mRNA

0.14 ± 0.12

1.09 ± 2.54

< 0.03

NALP 8 mRNA

0.14 ± 0.12

1.09 ± 2.54

< 0.03

NALP 9 mRNA

0.14 ± 0.12

1.25 ± 2.70

< 0.03

NALP 10 mRNA

0.14 ± 0.12

1.09 ± 2.54

< 0.03

NALP 11 mRNA

0.14 ± 0.12

1.09 ± 2.54

< 0.02

NALP 13 mRNA

0.14 ± 0.12

1.09 ± 2.54

< 0.03

IL-1B mRNA

8.71 ± 15.45

12.66 ± 16.68

< 0.02